COVID-19 vaccine intellectual property waiver decision

GPTKB entity

Predicate	Object
gptkbp:instanceOf	international policy decision
gptkbp:aimsTo	increasing global vaccine access waiving certain intellectual property rights for COVID-19 vaccines
gptkbp:appliesTo	developing countries with existing manufacturing capacity
gptkbp:criticizedFor	limited scope public health advocates slow negotiation process
gptkbp:date	June 2022
gptkbp:debatedBy	gptkb:WTO_member_states
gptkbp:duration	5 years (with possible extension)
gptkbp:excludes	therapeutics diagnostics
https://www.w3.org/2000/01/rdf-schema#label	COVID-19 vaccine intellectual property waiver decision
gptkbp:legalBasis	gptkb:TRIPS_Article_IX
gptkbp:negotiatedBy	G7 summit
gptkbp:opposedBy	gptkb:European_Union gptkb:Switzerland gptkb:United_Kingdom
gptkbp:proposedBy	gptkb:India gptkb:South_Africa
gptkbp:relatedTo	gptkb:World_Trade_Organization gptkb:TRIPS_Agreement gptkb:COVID-19_pandemic
gptkbp:resultedIn	limited waiver for COVID-19 vaccines
gptkbp:supportedBy	developing countries United States (from May 2021)
gptkbp:yearProposed	October 2020
gptkbp:bfsParent	gptkb:MC12
gptkbp:bfsLayer	6